The Federal Government says fast-acting insulin products Fiasp and Fiasp FlexTouch will be subsidised for patients with type 1 diabetes for an extra six months as part of an emergency stopgap measure.

Last week, Minister for Health and Aged Care Mark Butler issued a Supply Only arrangement after the sponsor Novo Nordisk announced it would remove the medication from the PBS on 1 April. 

This means the drug can still be dispensed, but not prescribed, under the PBS until the end of September for those with current scripts. 

Mr Butler also urged those affected to see their doctor for a fresh script before the PBS delisting date, as well as to discuss longer-term treatment alternatives.